The CASPIAN study evaluated the efficacy and safety of durvalumab plus tremelimumab and platinum-etoposide extensive-stage SCLC. touchONCOLOGY spoke to Niels Reinmuth (Munich, Germany) to discuss the characteristics of long-term survivors in the CASPIAN study.
Clinical Trial Identification: NCT03043872
Questions
- What did the CASPIAN study teach us about the efficacy and safety of durvalumab plus tremelimumab and platinum-etoposide extensive-stage SCLC? 00:18-01:58
- What was the rationale for your current analysis of CASPIAN data? 01:58-02:42
- What were the findings of this study and what are their clinical implications? 02:42-03:03
- What questions remain unanswered and what future studies are planned? 03:03-04:04
Speaker Disclosure: Niels Reinmuth is a Speaker’s Bureau participant with: Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Hoffmann-La Roche, MSD, Merck, Pfizer, and Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Congress 2022
